Particle.news
Download on the App Store
10 ARTICLES
·
last yr.

AstraZeneca Acquires Fusion Pharmaceuticals in $2.4 Billion Deal to Boost Cancer Treatment Pipeline

The acquisition marks a significant move into targeted cancer therapies, aiming to replace traditional treatments with more precise alternatives.

Image
Image
Image
Image

Overview

  • AstraZeneca acquires Fusion Pharmaceuticals for up to $2.4 billion, aiming to develop pioneering new cancer treatments.
  • The deal marks AstraZeneca's entry into the radioconjugate sector, targeting cancer cells with precision to minimize harm to healthy cells.
  • Fusion Pharmaceuticals' leading drug, FPI-2265, targets prostate cancer and is currently in phase II trials.
  • The acquisition is part of AstraZeneca's strategic expansion of its cancer treatment pipeline, following a series of acquisitions.
  • AstraZeneca's move is seen as a significant step towards replacing traditional cancer treatments like chemotherapy and radiotherapy with more targeted alternatives.